Lilly, Amylin, Alkermes to present clinical trials at EASD
INDIANAPOLIS Three drug companies said data they will present at a European diabetes conference later this month reinforce the safety and efficacy of a diabetes drug they developed.
Eli Lilly & Co., Amylin Pharmaceuticals and Alkermes said they would present data from more than 20 studies of the drug Byetta (exenatide) at the 45th Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria, which takes place between Tuesday and next Friday.
“EASD is a venue where researchers and clinical practitioners from around the world gather to discuss new developments in diabetes care,” Amylin SVP research and development Orville Kolterman said in a statement. “We look forward to participating in this exchange of ideas by presenting compelling data on the exenatide molecule.”